share_log

歌禮製藥-B：自願性公告 - 歌禮宣佈在2024年美國皮膚病學會(AAD)年會以壁報形式展示FASN抑制劑ASC40治療痤瘡II期研究最終結果

ASCLETIS-B: VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES POSTER PRESENTATION OF PHASE II STUDY FINAL RESULTS OF FASN INHIBITOR ASC40 FOR TREATMENT OF ACNE AT 2024 AAD ANNUAL MEETING

香港交易所 ·  Mar 10 20:00
Summary by Moomoo AI
歌禮製藥-B（歌禮）於2024年3月在美國聖疊戈舉行的美國皮膚病學會(AAD)年會上，展示了其FASN抑制劑ASC40治療痤瘡的II期研究最終結果。該研究是一項隨機、雙盲、安慰劑對照、多中心的臨床試驗，旨在評估ASC40對中度至重度尋常性痤瘡患者的療效和安全性。研究結果顯示，每日一次50毫克ASC40在12周治療期間，相較於安慰劑，顯著改善了痤瘡症狀，且安全性良好，未觀察到與藥物相關的嚴重不良事件。歌禮已獲得ASC40在大中華區的獨家開發、生產和商業化權益，並已啟動3期臨床試驗。董事會提醒投資者，尚無法保證ASC40最終能成功商業化。
歌禮製藥-B（歌禮）於2024年3月在美國聖疊戈舉行的美國皮膚病學會(AAD)年會上，展示了其FASN抑制劑ASC40治療痤瘡的II期研究最終結果。該研究是一項隨機、雙盲、安慰劑對照、多中心的臨床試驗，旨在評估ASC40對中度至重度尋常性痤瘡患者的療效和安全性。研究結果顯示，每日一次50毫克ASC40在12周治療期間，相較於安慰劑，顯著改善了痤瘡症狀，且安全性良好，未觀察到與藥物相關的嚴重不良事件。歌禮已獲得ASC40在大中華區的獨家開發、生產和商業化權益，並已啟動3期臨床試驗。董事會提醒投資者，尚無法保證ASC40最終能成功商業化。
CHANT PHARMACEUTICAL-B (ANTHEM) PRESENTED THE FINAL RESULTS OF A PHASE II STUDY OF ITS FASN INHIBITOR ASC40 TO TREAT ACNE AT THE AMERICAN SOCIETY OF DERMATOLOGY (AAD) ANNUAL MEETING IN ST. DIEGO, USA IN MARCH 2024. The study was a randomized, double-blind, placebo-controlled, multicenter clinical trial to evaluate the efficacy and safety of ASC40 in patients with moderate to severe unusual acne. The results showed that 50 mg of ASC40 once daily over 12 weeks of treatment significantly improved acne symptoms and had good safety and no drug-related serious adverse events were observed. Song has obtained exclusive development, production and commercialization rights for ASC40 in Greater China and has launched a 3-phase clinical trial. The Board of Directors reminds investors that ASC40 can not yet be guaranteed to be successfully commercialized.
CHANT PHARMACEUTICAL-B (ANTHEM) PRESENTED THE FINAL RESULTS OF A PHASE II STUDY OF ITS FASN INHIBITOR ASC40 TO TREAT ACNE AT THE AMERICAN SOCIETY OF DERMATOLOGY (AAD) ANNUAL MEETING IN ST. DIEGO, USA IN MARCH 2024. The study was a randomized, double-blind, placebo-controlled, multicenter clinical trial to evaluate the efficacy and safety of ASC40 in patients with moderate to severe unusual acne. The results showed that 50 mg of ASC40 once daily over 12 weeks of treatment significantly improved acne symptoms and had good safety and no drug-related serious adverse events were observed. Song has obtained exclusive development, production and commercialization rights for ASC40 in Greater China and has launched a 3-phase clinical trial. The Board of Directors reminds investors that ASC40 can not yet be guaranteed to be successfully commercialized.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more